L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment

L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment

Abstract Osimertinib, a mutant-specific third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is emerging as the preferred first-line of treatment for EGFR-mutant lung cancer. However, osimertinib resistance inevitably develops among patients treated with the drug...

Full description

Bibliographic Details
Main Authors: Meihui Li, Jing Qin, Fajun Xie, Lei Gong, Na Han, Hongyang Lu
Format: Article
Language:English
Published: Springer 2022-08-01
Series:Discover Oncology
Subjects:
L718Q/V mutation of EGFR exon 18
EGFR T790M mutation
Osimertinib
Resistance mechanism
Afatinib
Online Access:https://doi.org/10.1007/s12672-022-00537-7

Internet

https://doi.org/10.1007/s12672-022-00537-7

Similar Items